| Ytd | -9.50% | |
| 1y | 103.52% |
| Open | 1.71 | Prev Close | 1.70 | Low | 1.56 | High | 1.71 | Mkt Cap | 300.16M |
| Vol | 960.57K | Avg Vol | 2.29M | EPS | -1.33 | P/E | N/A | Forward P/E | -1.01 |
| Beta | N/A | Short Ratio | 4.59 | Inst. Own | 72.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.85 | 200-d Avg | 2.19 | 1yr Est | 11.77 |
Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform a
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics
Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the
HC Wainwright & Co. analyst Douglas Tsao maintains Neumora Therapeutics (NASDAQ:NMRA) with a
Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts work
US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech s
US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks dow
Neumora Therapeutics, Inc. (NASDAQ:NMRA) a clinical-stage biopharmaceutical company with a therapeut